^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Elecsys Anti-p53 Immunoassay

    Company:
    Roche
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 autoantibodies in human serum and plasma. Elecsys Anti-p53 is a high precision immunoassay, with a low turn-around time for testing, complementing our overall tumor marker portfolio. The new Elecsys Anti-p53 immunoassay uses the well-established electrochemiluminescence immunoassay “ECLIA” technology and is intended for use on cobas e immunoassay analyzers.
    Cancer:
    Breast Cancer, Colorectal Cancer, Head and Neck Cancer
    Method:
    Electrochemiluminescence Immunoassay (ECLIA)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    04/07/21
    BC
    -
    CE
    CRC
    -
    HNC
    -